With targeted degradation of FAK, we found an effective decrease in total FAK protein within 4 hours of FAK PROTAC treatment and a corresponding decrease in pY397 FAK expression in 24 hours in BRAF-mutant, KTC1 and KTC2, thyroid cancer cells (Figure 4A). This evidence concerns the gene BRAF and thyroid gland carcinoma.